Dec. 28 at 9:41 AM
$GENFF Five years ago, longevity science was fringe. Today:
• Big pharma is actively exploring aging pathways
• Billionaires and sovereign funds are backing longevity startups
• Regulators are warming to aging-related indications
Genflow is early, public, and overlooked — the exact combination that historically produces outsized returns before mainstream adoption.